Side-by-side · Research reference

TirzepatidevsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship14/45 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Tirzepatide

Vesugen

Primary target

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

Not applicable — does not operate via hormone axis

Origin

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

Tirzepatide

Vesugen

Standard dose (T2D)

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

—

Standard dose (weight)

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

—

Titration schedule

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

Indefinite for chronic indication

Case series report treatment courses in elderly arterial insufficiency

Reconstitution

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

—

Timing

Once weekly, any time of day

—

Half-life

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

Frequency

—

Not specified in available literature

04Side Effects & Safety

Parameter

Tirzepatide

Vesugen

GI symptoms

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

—

Injection site reaction

Mild erythema, pruritus

—

Pancreatitis risk

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

—

Hypoglycemia

Low as monotherapy; risk with sulfonylureas / insulin

—

Gallbladder events

Increased cholelithiasis

—

Pregnancy / OB

Contraindicated

—

Diabetic retinopathy

Rapid glycemic improvement may transiently worsen

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Vesugen

—

Relative Contraindications

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Tirzepatide

Vesugen

1. Reconstitution / device

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate weekly.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Once weekly, same day. Day change allowed if ≥3 days separate doses.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Needle

Pen-supplied. Research vial: 27–31G insulin syringe.

—

06Stack Synergy

Tirzepatide

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)